Allspring Global Investments Holdings LLC reduced its holdings in Encompass Health Co. (NYSE:EHC – Get Rating) by 55.6% in the 3rd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 7,626 shares of the company’s stock after selling 9,543 shares during the period. Allspring Global Investments Holdings LLC’s holdings in Encompass Health were worth $344,000 at the end of the most recent reporting period.
Several other hedge funds have also recently bought and sold shares of the business. Truist Financial Corp lifted its stake in Encompass Health by 2.6% in the 3rd quarter. Truist Financial Corp now owns 273,184 shares of the company’s stock worth $12,357,000 after acquiring an additional 6,910 shares in the last quarter. Wipfli Financial Advisors LLC purchased a new stake in Encompass Health in the 3rd quarter worth about $25,000. Fort Washington Investment Advisors Inc. OH lifted its stake in Encompass Health by 21.6% in the 3rd quarter. Fort Washington Investment Advisors Inc. OH now owns 267,267 shares of the company’s stock worth $12,088,000 after acquiring an additional 47,490 shares in the last quarter. Raymond James & Associates lifted its stake in Encompass Health by 7.0% in the 3rd quarter. Raymond James & Associates now owns 144,570 shares of the company’s stock worth $6,539,000 after acquiring an additional 9,429 shares in the last quarter. Finally, AE Wealth Management LLC purchased a new stake in Encompass Health in the 3rd quarter worth about $909,000. 96.14% of the stock is owned by hedge funds and other institutional investors.
Analyst Upgrades and Downgrades
EHC has been the subject of a number of recent research reports. Stephens cut their price target on Encompass Health from $60.00 to $58.00 and set an “overweight” rating for the company in a research note on Friday, October 28th. StockNews.com initiated coverage on Encompass Health in a research note on Wednesday, October 12th. They set a “hold” rating for the company. Raymond James raised their price target on Encompass Health from $65.00 to $72.00 and gave the stock a “strong-buy” rating in a research note on Friday, October 28th. Finally, TheStreet raised Encompass Health from a “c+” rating to a “b-” rating in a research note on Wednesday, December 21st. One equities research analyst has rated the stock with a hold rating, five have given a buy rating and one has given a strong buy rating to the stock. According to MarketBeat.com, Encompass Health presently has a consensus rating of “Buy” and a consensus price target of $64.13.
Encompass Health Stock Down 0.9 %
Encompass Health (NYSE:EHC – Get Rating) last issued its quarterly earnings data on Wednesday, October 26th. The company reported $0.67 earnings per share for the quarter, missing analysts’ consensus estimates of $0.68 by ($0.01). Encompass Health had a net margin of 5.39% and a return on equity of 15.59%. The company had revenue of $1.09 billion during the quarter, compared to the consensus estimate of $1.06 billion. As a group, research analysts predict that Encompass Health Co. will post 2.79 EPS for the current year.
Insider Activity at Encompass Health
In related news, Director Greg D. Carmichael acquired 1,830 shares of the business’s stock in a transaction that occurred on Monday, October 31st. The shares were acquired at an average cost of $54.67 per share, with a total value of $100,046.10. Following the purchase, the director now owns 10,546 shares of the company’s stock, valued at $576,549.82. The acquisition was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. 2.70% of the stock is owned by company insiders.
Encompass Health Profile
Encompass Health Corp. engages in the provision of post-acute healthcare services. It operates through the Inpatient Rehabilitation and Home Health and Hospice segments. The Inpatient Rehabilitation segment operates inpatient rehabilitation hospitals that provide rehabilitative treatment and care to patients who are recovering from stroke and other neurological disorders, cardiac and pulmonary conditions, brain and spinal cord injuries, complex orthopedic conditions and amputations.
- Get a free copy of the StockNews.com research report on Encompass Health (EHC)
- Pliant Therapeutics Gaps 34% Higher: More Upside To Come?
- How Will Early 2023 Layoffs Affect These 5 Biotech Stocks?
- Is the Pain Over for Baudax Bio Investors after a 70% Spike?
- Will Rocket Lab’s First U.S. Launch Send Stock Into Stratosphere?
- 3 Retail Stocks Ringing the Register in 2023
Receive News & Ratings for Encompass Health Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Encompass Health and related companies with MarketBeat.com's FREE daily email newsletter.